Baolingbao Biology Co.,Ltd. (SHE:002286)
China · Delayed Price · Currency is CNY 9.79
-0.07 (-0.71%)
Oct 31, 2025, 3:04 PM CST
Baolingbao Biology Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 144.09 | 111.16 | 53.97 | 133.17 | 201.58 | 49.86 | Upgrade |
Depreciation & Amortization | 119.5 | 119.52 | 122.74 | 105.63 | 104.98 | 96.26 | Upgrade |
Other Amortization | 11.26 | 11.25 | 8.02 | 4.13 | 5.09 | 6.91 | Upgrade |
Loss (Gain) From Sale of Assets | -0.41 | -0.41 | 0.05 | 0.05 | - | 1 | Upgrade |
Asset Writedown & Restructuring Costs | 30.22 | 30.22 | 12.74 | 4.36 | 3.57 | 0.35 | Upgrade |
Loss (Gain) From Sale of Investments | -1.9 | -1.9 | -1.9 | -5.92 | -25.27 | -3.6 | Upgrade |
Other Operating Activities | 35.6 | 7.81 | 22.59 | 14.37 | 21.23 | 19.89 | Upgrade |
Change in Accounts Receivable | -6.76 | -6.76 | 16.25 | 66.22 | -84.75 | 96.34 | Upgrade |
Change in Inventory | -17.05 | -17.05 | 49.79 | -53.48 | -70.67 | -30.45 | Upgrade |
Change in Accounts Payable | 7.33 | 7.33 | 15.49 | -237.66 | 51.66 | 155.12 | Upgrade |
Change in Other Net Operating Assets | -6.81 | -6.81 | -16.87 | - | - | 6.93 | Upgrade |
Operating Cash Flow | 309.44 | 248.72 | 282.28 | 30.82 | 206.27 | 398.46 | Upgrade |
Operating Cash Flow Growth | 76.59% | -11.89% | 815.86% | -85.06% | -48.23% | 158.82% | Upgrade |
Capital Expenditures | -207.06 | -189.93 | -152.23 | -254.55 | -92.85 | -131.93 | Upgrade |
Sale of Property, Plant & Equipment | - | - | 0.09 | 0.06 | 0.83 | 0.61 | Upgrade |
Investment in Securities | 53.95 | 30.59 | 1 | 119.49 | -99.75 | 10.05 | Upgrade |
Other Investing Activities | - | - | 3.04 | 5.31 | 16.26 | - | Upgrade |
Investing Cash Flow | -153.11 | -159.34 | -148.09 | -129.68 | -175.51 | -121.27 | Upgrade |
Long-Term Debt Issued | - | 349.8 | 289.58 | 543.8 | 452.14 | 349.95 | Upgrade |
Total Debt Issued | 294.6 | 349.8 | 289.58 | 543.8 | 452.14 | 349.95 | Upgrade |
Long-Term Debt Repaid | - | -371.26 | -502.69 | -440.46 | -301.52 | -604.95 | Upgrade |
Total Debt Repaid | -481.16 | -371.26 | -502.69 | -440.46 | -301.52 | -604.95 | Upgrade |
Net Debt Issued (Repaid) | -186.56 | -21.46 | -213.11 | 103.34 | 150.62 | -255 | Upgrade |
Issuance of Common Stock | 33.99 | - | - | - | 18.7 | - | Upgrade |
Repurchase of Common Stock | -0.22 | -7.06 | -7.28 | -0.69 | - | - | Upgrade |
Common Dividends Paid | -46.46 | -55.31 | -49.76 | -52.51 | -38.95 | -24.31 | Upgrade |
Other Financing Activities | 8.41 | 2.15 | - | 13 | 4 | 76.96 | Upgrade |
Financing Cash Flow | -190.84 | -81.68 | -270.14 | 63.14 | 134.37 | -202.36 | Upgrade |
Foreign Exchange Rate Adjustments | 4.81 | 5.54 | 0.09 | 3.73 | -3.29 | -4.27 | Upgrade |
Net Cash Flow | -29.7 | 13.24 | -135.86 | -31.99 | 161.84 | 70.56 | Upgrade |
Free Cash Flow | 102.37 | 58.79 | 130.05 | -223.72 | 113.42 | 266.53 | Upgrade |
Free Cash Flow Growth | 147.49% | -54.79% | - | - | -57.45% | 355.63% | Upgrade |
Free Cash Flow Margin | 3.80% | 2.45% | 5.15% | -8.25% | 4.10% | 12.97% | Upgrade |
Free Cash Flow Per Share | 0.28 | 0.16 | 0.36 | -0.60 | 0.30 | 0.75 | Upgrade |
Cash Income Tax Paid | 24.85 | 15.04 | -23.95 | -12.31 | 18.05 | 2.17 | Upgrade |
Levered Free Cash Flow | 71.01 | -5.68 | -30.89 | -372.39 | 67.94 | 316.62 | Upgrade |
Unlevered Free Cash Flow | 72.96 | 2.47 | -16.72 | -355.8 | 78.53 | 324.86 | Upgrade |
Change in Working Capital | -28.92 | -28.92 | 64.07 | -224.95 | -104.91 | 227.79 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.